Hello, Welcome to Shine Consultant !
Summit & Event Advisor & Insight Research & Analysis
Guest Information
发布时间: 2018 - 03 - 23
点击次数: 0
Positions: CTO/Co-Founder
Company: M3 Bioinformatics & Technology Inc
个人简介:
Dr. Jianwei Che received his bachelor degree in modern chemistry from the University of science and technology of China (USTC) in 1993, and Ph.D. in chemistry from University of California at San Diego (UCSD) in 1997. He did his postdoc at Caltech under Prof. William A. Goddard III studying nano materials using computational methods. He was among the first ones in the world who correctly predicted the thermal conductivity properties of carbon nanotubes. He has been doing research in computational chemistry, molecular modeling, cheminformatics and bioinformatics since graduate school. He joined the Genomics institute of the Novartis research foundation (GNF) in 2001 and developed many computational algorithms and software tools for drug discovery projects. He has published over 50 scientific papers and is a co-inventor of 10 international patents. He co-founded M3 Genomics in 2014 to develop NGS based genomic and epigenomic profiling technology for studying cancer samples. He currently serves as CTO for M3 Genomics and Life Healthcare Group Ltd.
发布时间: 2018 - 03 - 23
点击次数: 0
Positions: Co-founder\Lead of Big Data and AI R&D
Company: XtalPi Inc.
个人简介:
北京大学物理学和数学双学位学士,芝加哥大学物理学博士。 在麻省理工学院从事博士后研究期间创立XtalPi,并于2015年创立北京晶派科技有限公司,作为晶泰科技的全资子公司,进行大数据与人工智能相关技术的研发。曾供职美国最大的电子病历公司Epic System,对医药相关软件的开发与运作有深刻的了解。
发布时间: 2018 - 03 - 23
点击次数: 0
Positions: Health Informatics Director
Company: AstraZeneca
个人简介:
And outline: This talk will discuss the real world big data and advanced analytics that are uniquely presented in healthcare setting and pharma industry. Xia will speak about the strategic roadmap of applying big data analytics in full life cycle of medicines development spanning R&D and commercialization, then discuss several use cases of implementing big data analytics in AstraZeneca for insight generation and decision making.  Xia will conclude her talk by presenting the new paradigm shift in treatment from one-size-fit-all medicines to precision medicines, and summarize three key challenges yet exciting opportunities in the era of big data and analytics in healthcare and pharma.  My bio: Xia holds a director and senior leader position at Health Informatics team within advanced analytics center at AstraZeneca global medicines development unit.  Xia has records of accomplishment in applying novel data driven solutions and real world data analytics to all phases of medicines development life cycles from early drug discovery to late phase clinical development and commercialization. Xia has 17 years of experience in pharmaceutical industry with scientific focus spanning neuroscience, infection, diabetes, respiratory and autoimmune therapeutic areas. Currently Xia is leading informatics efforts in AstraZeneca Real World Evidence (RWE) to support clinical and observational studies, medicines comparative effectiveness, payer & pricing strategy and marketing accessing research. Prior to stepping into the clinical domain, Xia was with the AstraZeneca drug discovery in the areas of informatics and computational modeling to support candidate drug identification and optimization. Xia holds a Ph.D. in computational chemistry and has extensive training in broad areas of Informatics.
发布时间: 2018 - 03 - 23
点击次数: 0
Positions: Head of Data Science, Site Head of Pharma Research and Early Development Informatics
Company: Roche Innovation Center Shanghai
个人简介:
Dr. Qing Zhang is the Director of Informatics at Roche Innovation Center Shanghai, a member of China Management Team, and a member of global Data Science Leadership Team. His department manages research and early development data and workflows, performs data analysis, such as bioinformatics, cheminformatics, and information science studies, to impact decision making in drug discovery projects. Dr. Zhang has 19 years of molecular modeling and informatics practice and 10 years of drug discovery experience in multinational pharmaceutical companies. He is the co-inventor of 3 clinical candidates, has over 10 publications on international journals, and received multiple awards for technology innovations. Before joining Roche, Dr. Zhang was the Associate Director of Computational Chemistry at Amgen Asia R&D Center and was once the Principal Scientist at GSK R&D China. Dr. Zhang obtained a B.S. in physics (minor in computer science) from Fudan University in China and a Ph.D. in computational biomolecular chemistry from New York University in USA, which was followed by a postdoctoral training on computational molecular biology at The Scripps Research Institute in USA.